Stephen V Liu, Director of Thoracic Oncology, Chief, Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper
“Akeso reports Phase III HARMONi-A trial positive for survival.
Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m), but OS was in question. Full results to be presented at WCLC25.
How does this influence first-line choices?
FLAURA2 (osimertinib plus chemo) will be updated at WCLC25, showing an OS benefit over osi.
MARIPOSA (amivantamab + lazertinib) also showed an OS benefit over osi.
Will we want to avoid 1L chemo if HARMONi-A becomes the 2L standard? Depends on all of the details, the magnitude of the benefit. Stay tuned for WCLC25 from Barcelona!”
More posts featuring Stephen V Liu.